129 related articles for article (PubMed ID: 9352354)
21. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.
Chicz RM; Urban RG; Lane WS; Gorga JC; Stern LJ; Vignali DA; Strominger JL
Nature; 1992 Aug; 358(6389):764-8. PubMed ID: 1380674
[TBL] [Abstract][Full Text] [Related]
22. The P9 pocket of HLA-DQ2 (non-Aspbeta57) has no particular preference for negatively charged anchor residues found in other type 1 diabetes-predisposing non-Aspbeta57 MHC class II molecules.
Quarsten H; Paulsen G; Johansen BH; Thorpe CJ; Holm A; Buus S; Sollid LM
Int Immunol; 1998 Aug; 10(8):1229-36. PubMed ID: 9723710
[TBL] [Abstract][Full Text] [Related]
23. Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1.
Hennecke J; Carfi A; Wiley DC
EMBO J; 2000 Nov; 19(21):5611-24. PubMed ID: 11060013
[TBL] [Abstract][Full Text] [Related]
24. Evidence for cobinding of self- and allopeptides to human class II major histocompatibility antigen DR1 by energy transfer.
Kropshofer H; Max H; Kalbacher H
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):403-7. PubMed ID: 7678456
[TBL] [Abstract][Full Text] [Related]
25. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides.
Jardetzky TS; Brown JH; Gorga JC; Stern LJ; Urban RG; Strominger JL; Wiley DC
Proc Natl Acad Sci U S A; 1996 Jan; 93(2):734-8. PubMed ID: 8570625
[TBL] [Abstract][Full Text] [Related]
26. Naturally occurring A pocket polymorphism in HLA-B*2703 increases the dependence on an accessory anchor residue at P1 for optimal binding of nonamer peptides.
Griffin TA; Yuan J; Friede T; Stevanovic S; Ariyoshi K; Rowland-Jones SL; Rammensee HG; Colbert RA
J Immunol; 1997 Nov; 159(10):4887-97. PubMed ID: 9366414
[TBL] [Abstract][Full Text] [Related]
27. Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1.
Sato AK; Zarutskie JA; Rushe MM; Lomakin A; Natarajan SK; Sadegh-Nasseri S; Benedek GB; Stern LJ
J Biol Chem; 2000 Jan; 275(3):2165-73. PubMed ID: 10636922
[TBL] [Abstract][Full Text] [Related]
28. The N-terminal region of photocleavable peptides that bind HLA-DR1 determines the kinetics of fragment release.
Negroni MP; Stern LJ
PLoS One; 2018; 13(7):e0199704. PubMed ID: 29965980
[TBL] [Abstract][Full Text] [Related]
29. Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DR beta chain.
Davenport MP; Quinn CL; Chicz RM; Green BN; Willis AC; Lane WS; Bell JI; Hill AV
Proc Natl Acad Sci U S A; 1995 Jul; 92(14):6567-71. PubMed ID: 7604034
[TBL] [Abstract][Full Text] [Related]
30. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries.
Hammer J; Takacs B; Sinigaglia F
J Exp Med; 1992 Oct; 176(4):1007-13. PubMed ID: 1402647
[TBL] [Abstract][Full Text] [Related]
31. Involvement of class II beta-chain amino acid residues 85 and 86 in T-cell allorecognition.
Eckels DD; Geiger MJ; Sell TW; Gorski JA
Hum Immunol; 1990 Mar; 27(3):240-53. PubMed ID: 1692822
[TBL] [Abstract][Full Text] [Related]
32. Cooperativity during the formation of peptide/MHC class II complexes.
Anderson MW; Gorski J
Biochemistry; 2005 Apr; 44(15):5617-24. PubMed ID: 15823020
[TBL] [Abstract][Full Text] [Related]
33. Accuracy of a structural homology model for a class II histocompatibility protein, HLA-DR1: comparison to the crystal structure.
Nauss JL; Reid RH; Sadegh-Nasseri S
J Biomol Struct Dyn; 1995 Jun; 12(6):1213-33. PubMed ID: 7669268
[TBL] [Abstract][Full Text] [Related]
34. A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding.
Zarutskie JA; Sato AK; Rushe MM; Chan IC; Lomakin A; Benedek GB; Stern LJ
Biochemistry; 1999 May; 38(18):5878-87. PubMed ID: 10231540
[TBL] [Abstract][Full Text] [Related]
35. Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II.
Hudson KR; Tiedemann RE; Urban RG; Lowe SC; Strominger JL; Fraser JD
J Exp Med; 1995 Sep; 182(3):711-20. PubMed ID: 7650479
[TBL] [Abstract][Full Text] [Related]
36. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide.
Stern LJ; Brown JH; Jardetzky TS; Gorga JC; Urban RG; Strominger JL; Wiley DC
Nature; 1994 Mar; 368(6468):215-21. PubMed ID: 8145819
[TBL] [Abstract][Full Text] [Related]
37. High-throughput engineering and analysis of peptide binding to class II MHC.
Jiang W; Boder ET
Proc Natl Acad Sci U S A; 2010 Jul; 107(30):13258-63. PubMed ID: 20622157
[TBL] [Abstract][Full Text] [Related]
38. Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding.
Jardetzky TS; Gorga JC; Busch R; Rothbard J; Strominger JL; Wiley DC
EMBO J; 1990 Jun; 9(6):1797-803. PubMed ID: 2189723
[TBL] [Abstract][Full Text] [Related]
39. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules.
Malcherek G; Gnau V; Jung G; Rammensee HG; Melms A
J Exp Med; 1995 Feb; 181(2):527-36. PubMed ID: 7836909
[TBL] [Abstract][Full Text] [Related]
40. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1.
Xu M; Jackson R; Adams S; Humphreys RE
Arzneimittelforschung; 1999 Sep; 49(9):791-9. PubMed ID: 10514908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
